In addition, nilotinib was also able to promote accumulation of GATA1 in the presence of the RNA polymerase I inhibitor CX‐5461, which impaired erythroid differentiation of K562 cells (Fig 6C and D) and is widely used to model ribosomopathies, such as Diamond‐Blackfan anemia (DBA) (Khajuria et al, 2018). This evidence concerns the gene GATA1 and Diamond-Blackfan anemia.